Show simple item record

dc.contributor.authorHalkett, Georgia
dc.contributor.authorWigley, C.
dc.contributor.authorAoun, Samar
dc.contributor.authorPortaluri, M.
dc.contributor.authorTramacere, F.
dc.contributor.authorLivi, L.
dc.contributor.authorDetti, B.
dc.contributor.authorArcangeli, S.
dc.contributor.authorLund, J.
dc.contributor.authorKristensen, A.
dc.contributor.authorMcFadden, N.
dc.contributor.authorGrun, A.
dc.contributor.authorBydder, S.
dc.contributor.authorSackerer, I.
dc.contributor.authorGreimel, E.
dc.contributor.authorSpry, N.
dc.contributor.authorEORTC Quality of Life Group
dc.date.accessioned2018-12-13T09:08:40Z
dc.date.available2018-12-13T09:08:40Z
dc.date.created2018-12-12T02:46:25Z
dc.date.issued2018
dc.identifier.citationHalkett, G. and Wigley, C. and Aoun, S. and Portaluri, M. and Tramacere, F. and Livi, L. and Detti, B. et al. 2018. International validation of the EORTC QLQ-PRT20 module for assessment of quality of life symptoms relating to radiation proctitis: a phase IV study. Radiation Oncology. 13 (1): Article ID 162.
dc.identifier.urihttp://hdl.handle.net/20.500.11937/71050
dc.identifier.doi10.1186/s13014-018-1107-x
dc.description.abstract

Background: Although patients experience radiation proctitis post radiotherapy no internationally tested instruments exist to measure these symptoms. This Phase IV study tested the scale structure, reliability and validity and cross-cultural applicability of the EORTC proctitis module (QLQ-PRT23) in patients who were receiving pelvic radiotherapy. Methods: Patients (n = 358) from six countries completed the EORTC QLQ-C30, QLQ-PRT23 and EORTC Quality of Life Group debriefing questions. Clinicians completed the EORTC Radiation Therapy Oncology Group scale. Questionnaires were completed at four time-points. The module’s scale structure was examined and validated using standard psychometric analysis techniques. Results: Three items were dropped from the module (QLQ-PRT23 → QLQ-PRT20). Factor analysis identified five factors in the module: bowel control; bloating and gas; emotional function/lifestyle; pain; and leakage. Inter-item correlations were within r = 0.3–0.7. Test-Retest reliability was high. All multi-item scales discriminated between patients showing symptoms and those without symptomology. The module discriminated symptoms from the clinician completed scoring and for age, gender and comorbidities. Conclusion: The EORTC QLQ-PRT20 is designed to be used in addition to the EORTC QLQ-C30 to measure quality of life in patients who receive pelvic radiotherapy. The EORTC QLQ-PRT20 is quick to complete, acceptable to patients, has good content validity and high reliability. Trial registration: Australian and New Zealand Clinical Trials Registry (ANZCTR) ACTRN12609000972224.

dc.publisherElsevier
dc.relationhttps://ro-journal.biomedcentral.com/
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.titleInternational validation of the EORTC QLQ-PRT20 module for assessment of quality of life symptoms relating to radiation proctitis: a phase IV study
dc.typeJournal Article
dcterms.source.volume13
dcterms.source.number1
dcterms.source.issn1748-717X
dcterms.source.titleRadiation Oncology
curtin.departmentSchool of Nursing, Midwifery and Paramedicine
curtin.accessStatusOpen access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

http://creativecommons.org/licenses/by/4.0/
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/